How to Get $35 Insulin in 2026 With Private Insurance: Manufacturer Programs, State Caps, and the INSULIN Act 2026

If you have Medicare, insulin has been capped at $35 per month since 2023. If you have private insurance, or no insurance, that cap has never applied to you. The Inflation Reduction Act carved out Medicare and no one else. It's the single most confusing thing about insulin pricing in 2026 — ads celebrate the $35 cap, patients walk to the counter, and half of them are told their copay is $130, $260, or higher.

The good news: for almost everyone with a Type 1 or Type 2 diagnosis in 2026, there is a legal, legitimate path to $35-per-month insulin without waiting for Congress. Three big manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — run their own $35 savings programs that work with most commercial plans and for uninsured patients. Thirty states have added their own copay caps for state-regulated plans. And in July 2026, a bipartisan Senate bill (the INSULIN Act of 2026) cleared committee that would finally make the $35 cap federal for everyone.

This guide walks through which program applies to you, the exact script to give your pharmacist, the tax and insurance interactions that trip patients up, and what to do if none of the above works.

The 2022 Inflation Reduction Act (IRA) set two insulin protections that took effect for 2023 and later: the $35 monthly cap for Medicare Part D covered insulins, and the same cap for insulin delivered through Medicare Part B durable medical equipment (mostly pumps). Both apply with no deductible.

An amendment to extend that cap to commercial insurance failed to reach the 60-vote threshold during the IRA vote. So the statute went into law with a Medicare-only cap. In 2026 the federal cap still applies only to the roughly 66 million Americans on Medicare. Everyone else — commercial insurance, marketplace plans, employer plans, and the uninsured — falls back on a patchwork of state caps, manufacturer coupons, and biosimilars.

Eli Lilly, Novo Nordisk, and Sanofi together manufacture the vast majority of insulin used in the United States. Each has a savings program that can bring monthly cost down to $35 or less for eligible patients. All three enroll online or by phone in about 10 minutes; none require prior authorization from your insurer; and all three can be presented at the pharmacy counter as a co-pay card that adjusts your out-of-pocket at checkout.

Eli Lilly Insulin Value Program

Covers Humalog (insulin lispro), Basaglar (insulin glargine), Lyumjev (insulin lispro-aabc), and the Lilly-authorized biosimilar of Humalog. Any legal U.S. resident with commercial insurance or without insurance can enroll. The card caps your monthly out-of-pocket at $35 for up to a 30-day supply. Enrollment at insulinaffordability.com. You will get a virtual pharmacy card in your email within a few minutes; screenshot it and hand it to the pharmacy tech.

Novo Nordisk MyInsulinRx

Covers NovoLog (insulin aspart), NovoLog Mix, Levemir (in states where still stocked), Tresiba (insulin degludec), and Fiasp. Cap is $35/month with commercial insurance; uninsured patients can use the Novo Nordisk Patient Assistance Program instead (income limit: 400% of the federal poverty level, which is roughly $62,600 for an individual in 2026). Novo also runs a My$99Insulin program giving any patient regardless of insurance status a 90-day supply for $99 — useful for anyone who briefly loses coverage.

Sanofi Insulins Valyou Savings Program

Covers Lantus (insulin glargine), Toujeo (insulin glargine U-300), Admelog (insulin lispro), and Apidra (insulin glulisine). Cap is $35 for a 30-day supply. Uninsured patients qualify; commercial insurance stacks with the program.

Beginning with Colorado in 2019, states have been passing insulin copay caps that apply to plans regulated by the state insurance department. By mid-2026, roughly 30 states have laws on the books. The caps vary widely and each state's law defines its own list of covered insulins.

The critical footnote: state caps only apply to state-regulated insurance. That means individual plans, small-group employer plans, and marketplace ACA plans. Self-funded employer plans (about 65% of employer-sponsored coverage) are regulated by federal ERISA law and are exempt from state caps. If you work for a large employer, there's a strong chance your plan is self-funded even if the name on the card is a familiar insurer.

How to Tell Which Type of Plan You Have

Call the member services number on the back of your insurance card and ask exactly: "Is my plan fully insured or self-funded?" The answer determines whether your state's cap applies to you. It's a fair, standard question and the representative will answer directly. Also check the plan documents — a self-funded plan usually says "administered by" your insurer, while a fully-insured plan says "insured by."

Here is the exact sequence to run at pickup if you're presenting a manufacturer card for the first time. It works whether you're at CVS, Walgreens, Kroger, a grocery-store pharmacy, or a mail-order operation.

1. Enroll first, in advance. The manufacturer sites process enrollment in under 10 minutes and email a card ID immediately. Doing this in the pharmacy line adds 20 minutes.
2. Hand over your insurance card and the manufacturer card at the same time. Say: "Please run my primary insurance first, then apply the manufacturer copay card as secondary." The pharmacy system will bill your plan, then the manufacturer program picks up the balance up to the $35 cap.
3. If the pharmacy tech says the card won't process: Ask them to run the BIN, PCN, and Group numbers from the manufacturer card as a secondary claim. If it still fails, the pharmacist can call the manufacturer help line printed on the card — usually a five-minute fix.
4. If your out-of-pocket at checkout is more than $35: Do not pay yet. Ask the pharmacist to verify that both cards ran. Occasionally a pharmacy system will silently drop the secondary card.
5. Save the receipt. If you were overcharged, the manufacturer program will refund the difference on submitted receipts.

Interchangeable biosimilar insulins are FDA-approved to be dispensed in place of their brand-name reference product without a new prescription. As of 2026, the two dominant interchangeable biosimilars are Semglee (insulin glargine-yfgn, interchangeable with Lantus) and Rezvoglar (insulin glargine-aglr, interchangeable with Lantus). Basaglar is also an approved biosimilar of Lantus but is not classified as interchangeable in every state.

List prices for interchangeable biosimilars run 65 to 78 percent below the reference product. Many commercial plans in 2026 have moved biosimilars to a preferred formulary tier with copays under $25 per month — often lower than what a $35 manufacturer program would deliver, and lower than most state caps.

If your endocrinologist wrote the prescription for Lantus, ask your pharmacist whether an interchangeable biosimilar is available and cheaper. In most states the pharmacist can substitute the biosimilar for the reference product without calling the prescriber. If your state requires a new prescription, ask your prescriber for one at the next appointment; the switch is clinically equivalent.

S. 4189, the INSULIN Act of 2026, is a bipartisan bill that would extend the $35 monthly insulin cap to all commercial insurance plans, matching the current Medicare rule. It cleared a Senate Health, Education, Labor and Pensions committee hearing in July 2026. A companion bill has been introduced in the House. Neither has yet passed either chamber, and the current legislative calendar makes 2026 enactment uncertain.

Key provisions if enacted:

• Federal $35 monthly cap on all covered insulins for private commercial plans, including self-funded ERISA plans.
• No deductible; cap applies from the first fill of the plan year.
• Manufacturer rebate transparency requirements for insurers.
• Extension of the cap to uninsured patients through a federal patient assistance backstop.

Until enactment, the practical takeaway is: don't wait for Congress. The manufacturer programs and state caps described above already deliver $35 pricing for the large majority of patients today.

Insulin has been an eligible expense for both HSAs and FSAs since long before the current caps. In 2026 nothing about that has changed, but a few interactions with the $35 cap are worth understanding.

You Can Still Pay With an HSA at $35

If you use a manufacturer copay card or fall under a state cap, you can pay the discounted $35 with HSA funds. The IRS considers the out-of-pocket amount — not the sticker price — to be the qualified medical expense. The pharmacy receipt is your substantiation.

Manufacturer Cards Do Not Affect HDHP Status

A common concern: does using a manufacturer copay card count as "other coverage" that would disqualify you from an HSA-eligible HDHP? The IRS has issued informal guidance saying no. Manufacturer patient assistance programs are not treated as third-party health coverage for HDHP purposes.

Insulin Is Also Preventive Under Safe Harbor

Since 2020, HDHPs have been allowed to cover insulin and certain other diabetes management drugs before the deductible under IRS Notice 2019-45. Ask your plan whether it applies preventive-drug safe harbor to insulin. If it does, your insulin may be at low or no copay even before you meet the deductible — which is often better than the $35 cap.

A small subset of patients — mostly on newer or less common insulin analogs, or on formulations excluded from a specific plan formulary — still face high out-of-pocket cost after checking every program. The fallback options in 2026:

340B Community Health Centers

Federally qualified health centers (FQHCs) participate in the 340B Drug Pricing Program, which lets them dispense insulin at deeply discounted prices to eligible patients. Find your nearest FQHC at findahealthcenter.hrsa.gov. Sliding-scale fees apply, based on income.

Walmart ReliOn Insulin

Walmart sells an authorized ReliOn-branded version of NovoLog (insulin aspart) and Novolin at flat cash prices — roughly $73 per vial for the analog and $25 for the older Novolin. No insurance required, no enrollment. Note this is a limited product line; you will need a prescription in your name.

Formal Formulary Exception Request

If your plan covers one insulin but your endocrinologist prescribed a different one, file a formulary exception. The clinical criteria: your prescriber must attest that the plan's preferred insulin would be less effective or more likely to cause an adverse reaction for you. The plan must respond within 72 hours (24 hours for urgent requests).

State Insurance Complaint

If your state has an insulin cap and your plan is state-regulated, but you're being charged above the cap, file a complaint with your state department of insurance. These complaints are typically resolved in 2 to 6 weeks and often result in a refund plus the correct pricing going forward.

Dana is 42, has Type 1 diabetes, and is on Humalog (three cartridges per month) and Lantus (one vial per month). She has a commercial PPO through her spouse's employer. First fill of 2026 came back at $128 for Humalog and $174 for Lantus — $302 for one month of insulin.

What she did, in order:

1. Verified plan type: Called member services; the plan is self-funded. So Illinois' $100 state cap does not apply to her.
2. Enrolled in the Lilly Insulin Value Program for Humalog. Ten minutes at insulinaffordability.com; received a virtual card immediately.
3. Enrolled in the Sanofi Valyou Program for Lantus. Ten more minutes.
4. Asked her prescriber to check whether Semglee (an interchangeable Lantus biosimilar) was on her plan's preferred tier. It was — at a $22 copay before any coupon.
5. Switched the Lantus prescription to Semglee and kept the Lilly card for Humalog.

Her new monthly total: $22 for Semglee plus $35 for Humalog = $57, versus $302 without any of the above. Total 2026 savings: about $2,940. She pays with her HSA and keeps receipts for substantiation.

Do these programs work at every pharmacy?

Almost all retail pharmacies and independent pharmacies process manufacturer copay cards. Some mail-order and specialty pharmacies do not. If you use a mail-order pharmacy, call ahead and ask whether they process secondary manufacturer claims for your specific insulin.

Do I have to re-enroll every year?

Yes, in most cases. The three big programs run on annual enrollment cycles that reset in January. Set a calendar reminder for the last week of December to re-enroll for the coming year; otherwise your card can silently expire and your January refill will come in at full copay.

What if my endocrinologist prescribed an insulin not on any of these programs?

The three big programs cover the large majority of prescription volume, but not every single insulin. If yours is not covered — certain compounded, imported, or newer analogs — ask your prescriber about a clinically equivalent alternative that is covered, or file a formulary exception request through your plan.

Are pen needles and glucose test strips also capped?

No. The Medicare $35 cap, the state caps, and the manufacturer programs all apply only to the insulin itself. Pen needles, syringes, test strips, continuous glucose monitor supplies, and insulin pumps have separate coverage rules. Many are covered as durable medical equipment under Part B (for Medicare) or as pharmacy benefits for commercial insurance.

What happens if the INSULIN Act passes mid-year?

Typical implementation is a plan-year transition, meaning the cap would apply starting with the next plan year (January 1, 2027 for most calendar-year plans). Some bills include an accelerated effective date. Watch for the enacted language.

If you are paying more than $35 per month for insulin in 2026, three concrete steps will resolve most cases within a week:

First, identify the manufacturer of every insulin you take. Lilly makes Humalog, Basaglar, Lyumjev. Novo Nordisk makes NovoLog, Tresiba, Fiasp, Levemir. Sanofi makes Lantus, Toujeo, Admelog, Apidra. Enroll in the corresponding manufacturer program before your next refill.

Second, ask your pharmacist about biosimilar options. For basal insulin on Lantus, Semglee or Rezvoglar are usually cheaper than the brand-plus-coupon route. This is a two-minute conversation at pickup.

Third, if you live in a cap state and have state-regulated insurance, confirm your plan is honoring the cap. Call member services and ask specifically: "Under [State] state insulin copay cap law, my out-of-pocket for insulin should not exceed [$X] per 30-day supply. Please verify this is being applied to my prescriptions." A recorded call is a strong record if you later need to escalate to the state department of insurance.